From Name:
From Email:
To Name:
To Email:

Optional Message:

Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients

from Journal for Immunotherapy of Cancer

Checkpoint inhibitors have revolutionized the treatment of cancer, but their use remains limited by off-target inflammatory and immune-related adverse events. Solid organ transplantation recipients have been excluded from clinical trials owing to concerns about alloimmunity, organ rejection, and immunosuppressive therapy. Thus, scientists conducted a retrospective study and literature review to evaluate the safety of CPIs in patients with cancer and prior SOT. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063